PRM — Big Pharma Split Balance Sheet
0.000.00%
- CA$13.30m
- -CA$12.91m
- CA$0.66m
- 76
- 81
- 40
- 72
Annual balance sheet for Big Pharma Split, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 22.6 | 36.7 | 24.5 | 25.7 | 26.2 |
Net Total Receivables | 0.299 | 1.07 | 14.5 | 0.795 | 0.097 |
Total Current Assets | 22.9 | 37.8 | 39.1 | 26.5 | 26.3 |
Total Assets | 22.9 | 37.8 | 39.1 | 26.5 | 26.3 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.4 | 0.548 | 9.51 | 0.386 | 1.05 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.4 | 0.548 | 9.51 | 0.386 | 1.05 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Total Equity | 22.5 | 37.3 | 29.6 | 26.1 | 25.3 |
Total Liabilities & Shareholders' Equity | 22.9 | 37.8 | 39.1 | 26.5 | 26.3 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |